Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,335,848
  • Shares Outstanding, K 95,300
  • Annual Sales, $ 37,310 K
  • Annual Income, $ -366,250 K
  • EBIT $ -574 M
  • EBITDA $ -555 M
  • 60-Month Beta 1.74
  • Price/Sales 131.74
  • Price/Cash Flow N/A
  • Price/Book 2.45

Options Overview Details

View History
  • Implied Volatility 67.59% (+5.63%)
  • Historical Volatility 56.98%
  • IV Percentile 80%
  • IV Rank 53.89%
  • IV High 83.16% on 10/15/25
  • IV Low 49.39% on 01/21/25
  • Expected Move (DTE 7) 3.41 (5.86%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 13,419
  • Volume Avg (30-Day) 7,059
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 128,398
  • Open Int (30-Day) 131,659
  • Expected Range 54.77 to 61.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.16
  • Number of Estimates 11
  • High Estimate -0.81
  • Low Estimate -1.58
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -163.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.02 +21.16%
on 11/21/25
59.77 -2.66%
on 12/04/25
+1.77 (+3.14%)
since 11/04/25
3-Month
48.02 +21.16%
on 11/21/25
78.48 -25.87%
on 10/08/25
+5.44 (+10.31%)
since 09/04/25
52-Week
30.04 +93.68%
on 04/07/25
78.48 -25.87%
on 10/08/25
+7.04 (+13.77%)
since 12/04/24

Most Recent Stories

More News
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

CRSP : 58.18 (+3.91%)
VRTX : 457.36 (-1.25%)
Healthcare's Shift to Prevention Gains Momentum as Markets Reach Critical Mass

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Longevity science advances reveal how genes from supercentenarians can reverse cardiac aging[1], while...

HUM : 253.02 (-1.52%)
AVAI : 0.2951 (-1.63%)
CRSP : 58.18 (+3.91%)
VRTX : 457.36 (-1.25%)
MNKD : 5.71 (+2.15%)
Crispr Therapeutics AG (CRSP) Receives a Buy from Citizens JMP

Citizens JMP analyst Silvan Tuerkcan reiterated a Buy rating on Crispr Therapeutics AG today and set a price target of $86.00. The company’s shares closed last Friday at $73.07.Elevate Your Investing...

CRSP : 58.18 (+3.91%)
Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG. The company’s shares closed last Friday at $73.07.Elevate Your Investing Strategy: Take advantage...

CRSP : 58.18 (+3.91%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

AVAI : 0.2951 (-1.63%)
CRSP : 58.18 (+3.91%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

/CNW/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant...

AVAI : 0.2951 (-1.63%)
CRSP : 58.18 (+3.91%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

MarketNewsUpdates News Commentary

CRSP : 58.18 (+3.91%)
AVAI : 0.2951 (-1.63%)
TEM : 76.33 (+1.90%)
BNTX : 96.00 (-0.75%)
BMY : 51.95 (+1.94%)
This Is How You Can Hedge Your Bets on Tesla Stock and ‘The Largest AI Project on Earth’

Cathie Wood sees Tesla as the largest AI project on Earth, but investors may find steadier upside in her flagship ARKK ETF.

AB : 41.58 (+1.39%)
ROKU : 94.54 (+1.68%)
AAPL : 280.70 (-1.21%)
^ETHUSD : 3,141.679 (+0.51%)
ARKW : 156.17 (+1.40%)
$NASX : 23,505.14 (+0.22%)
$SPX : 6,857.12 (+0.11%)
ARKQ : 114.78 (+2.15%)
COIN : 274.05 (-1.04%)
ARKK : 82.65 (+2.35%)
SHOP : 162.31 (+1.44%)
TSLA : 454.53 (+1.74%)
New Strong Sell Stocks for August 1st

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:CRISPR Therapeutics AG CRSP is a gene editing company. The Zacks Consensus Estimate for its current year earnings has been revised...

CRSP : 58.18 (+3.91%)
CSTL : 39.62 (+0.53%)
SIGI : 77.10 (-1.22%)
New Strong Sell Stocks for July 29th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Burford Capital Limited BUR is a legal finance products and services company. The Zacks Consensus Estimate for its current year...

CNL : 11.44 (+0.04%)
CRSP : 58.18 (+3.91%)
BUR : 9.18 (-3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 65.16
2nd Resistance Point 62.47
1st Resistance Point 60.32
Last Price 58.18
1st Support Level 55.48
2nd Support Level 52.79
3rd Support Level 50.64

See More

52-Week High 78.48
Fibonacci 61.8% 59.98
Last Price 58.18
Fibonacci 50% 54.26
Fibonacci 38.2% 48.54
52-Week Low 30.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar